• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Corium

Corium launches transdermal patch for treating Alzheimer’s

September 29, 2022 By Sean Whooley

Corium

Corium (Nasdaq:CORI) today announced the availability of Adlarity (donepezil transdermal system) for prescription use in the U.S. Adlarity, a once-weekly patch, delivers consistent doses of donepezil through the skin. It treats patients with mild, moderate, or severe dementia of the Alzheimer’s type. It holds FDA approval — the first and only — for  5 mg/day […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Neurological, Pharmaceuticals Tagged With: Corium

Study backs Corium’s transdermal Alzheimer’s dementia treatment

August 2, 2022 By Sean Whooley

Corium

Corium (NSDQ:CORI) announced that studies support its once-weekly Adlarity transdermal treatment for Alzheimer’s dementia. Adlarity (donepezil transdermal system) demonstrated the ability to maintain equivalent daily exposure of donepezil when compared to oral formulations of donepezil, along with a favorable overall gastrointestinal (GI) side effect profile. The treatment uses Corium’s proprietary Corplex technology, delivering continuous, controlled, […]

Filed Under: Featured, Neurological, Pharmaceuticals Tagged With: Corium

Corium touts study results for once-daily ADHD capsule

October 14, 2021 By Sean Whooley

Corium

Corium (NSDQ:CORI) today announced clinical data demonstrating the strong performance of its once-daily ADHD capsule. Boston-based Corium’s Azstarys oral capsule for treating ADHD symptoms (serdexmethylphenidate [SDX] and dexmethylphenidate [d-MPH]) received FDA approval in March as the first and only product containing a d-MPH oral prodrug for treating ADHD (attention deficit hyperactivity disorder) symptoms in patients […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Neurological, Pharmaceuticals Tagged With: Corium

FDA to make decision on Corium’s transdermal patch for treating dementia next year

October 12, 2021 By Sean Whooley

Corium

Corium (NSDQ:CORI) announced today that the FDA set a Prescription Drug User Fee (PDUFA) target action date for its Adlarity system. The FDA set the PDUFA target action date for Adlarity (donepezil transdermal system), a transdermal patch designed to treat dementia or Alzheimer’s disease, for March 11, 2022. If approved, Boston-based Corium’s once-weekly Adlarity patch […]

Filed Under: Business/Financial News, Drug-Device Combinations, Food & Drug Administration (FDA), Neurological, Pharmaceuticals, Regulatory/Compliance Tagged With: Corium, FDA

FDA clears once-daily ADHD capsule from Corium

March 3, 2021 By Sean Whooley

Corium

Corium (NSDQ:CORI) announced today that it received FDA approval for its once-daily Azstarys oral capsule for treating ADHD symptoms. Boston-based Corium touts its Azstarys (serdexmethylphenidate [SDX] and dexmethylphenidate [d-MPH]) drug as the first and only product containing a d-MPH oral prodrug for treating ADHD (attention deficit hyperactivity disorder) symptoms in patients aged six years and older, […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Neurological, Pediatrics, Pharmaceuticals, Regulatory/Compliance Tagged With: Corium

Corium touts clinical data for transdermal delivery of Alzheimer’s drug

July 18, 2017 By Sarah Faulkner

Corium

Corium (NSDQ:CORI) touted data today from a pilot bioequivalence study, comparing its Corplex Donepezil transdermal patch to oral Aricept as delivery method for the most commonly prescribed treatment for Alzheimer’s disease. Data from the pilot study demonstrated that Corium’s transdermal patch met the criteria for bioequivalence to oral Aricept, as measured by primary pharmacokinetic endpoints […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Neurological, Pharmaceuticals, Research & Development, Wall Street Beat Tagged With: Corium

Corium poised for $66M IPO for wearable drug-delivery devices

March 24, 2014 By drugdelivery

Corium poised for $66M IPO for wearable drug-delivery devices

Drug-delivery devices maker Corium could raise up to $66 million through an initial public offering, the company announced in SEC filings today.

Corium plans to offer 5.5 million shares of common stock for $10-$12 apiece, putting its total offering value at between $55-$66 million. At the middle rate of $11 per share, Corium expects its net proceeds to amount to $53.7 million after expenses.

Filed Under: Drug-Device Combinations Tagged With: Corium

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS